Included in the formulation
АТХ:C.08.E.A.01 Fendilin
C.08.E.A Phenylalkylamine derivatives
Pharmacodynamics:Non-selective calcium channel blocker, including L-type. It has antianginal, antiarrhythmic, coronarodilating and hypotensive action. Prevents the entry of extracellular calcium into cardiomyocytes and muscle cells of the coronary and peripheral arteries. In high doses, it inhibits the release of calcium ions from intracellular stores. Does not affect the tone of the veins.
Strengthens the coronary blood flow, improving the blood supply of ischemic zones of the myocardium, does not cause a "robbery syndrome". Expands peripheral arteries, reduces overall peripheral resistance, postnagruzku and the need for myocardium in oxygen. Suppresses the automatism of the sinus node and the conductivity along the atrioventricular compound (prolongation of the QRS complex and PQ and QT intervals on an electrocardiogram). Reflex activation of the sympathoadrenal system overlaps the negative chrono-, dromo- and inotropic effects due to an increase in the heart rate in response to peripheral vasodilation.
Reduces pulmonary hypertension, dilates the bronchi. It enhances kidney blood flow, causes a moderate natriuresis.
Pharmacokinetics:After oral administration, up to 98% is absorbed in the gastrointestinal tract. The maximum concentration in the blood plasma is achieved in 1-2 hours. The connection with plasma proteins is 90%.
Penetrates through blood-brain and placental barriers, it is found in breast milk. Metabolism in the liver.
The half-life is 6-8 hours. Elimination by the kidneys.
Indications:It is used for the treatment of hypertension, supraventricular tachycardia, vasospastic angina, hypertrophic cardiomyopathy, Raynaud's disease, atherosclerosis of the coronary vessels, obliterating diseases of the vessels of the lower extremities. Used to prevent repeated myocardial infarction and sudden death.
IX.I10-I15.I10 Essential [primary] hypertension
IX.I10-I15.I15 Secondary Hypertension
IX.I70-I79.I70.2 Atherosclerosis of the arteries of the extremities
IX.I20-I25.I25.1 Atherosclerotic Heart Disease
IX.I70-I79.I73.0 Raynaud's syndrome
IX.I70-I79.I73.1 Obliterating thromboangitis [Berger's disease]
IX.I30-I52.I42 Cardiomyopathy
IX.I30-I52.I47.1 Nadzheludochkovaya tachycardia
IX.I70-I79.I70 Atherosclerosis
IX.I70-I79.I70.9 Generalized and unspecified atherosclerosis
Contraindications:Acute myocardial infarction, unstable angina, aortic stenosis, aortic hypotension, bradycardia, atrioventricular block II degree, sinoatrial blockade, cardiogenic shock, individual intolerance, children under 18 years of age.
Carefully:Impaired renal and hepatic function, hypersensitivity.
Pregnancy and lactation:Recommendations for FDA - Category C. Contraindicated in pregnancy and lactation.
Dosing and Administration:Inside, 50-100 mg 3 times a day.
The highest daily dose: 300 mg.
The highest single dose: 100 mg.
Side effects:Central and peripheral nervous system: dizziness, headache, stupor, anxiety.
The cardiovascular system: arterial hypotension, bradycardia, reddening of the face, progression of symptoms of heart failure.
Digestive system: nausea, xerostomia, gastralgia, indigestion.
Dermatological reactions: a rash.
Allergic reactions.
Overdose:Cases of overdose are not described.
Treatment is symptomatic. Antidotes are calcium preparations.
Interaction:Incompatible with alcohol. The intake of grapefruit juice slows the absorption of the drug.
With the simultaneous use of the drug with antihypertensive drugs, as well as with inhalational anesthetics, tricyclic antidepressants, nitrates, cimetidine, diuretics, the hypotensive effect intensifies.
Incompatible with rifampicin, it accelerates the metabolism of slow calcium channel blockers.
Increases the concentration of indirect anticoagulants in blood plasma.
Special instructions:Stop taking the drug should be gradual.
Before an operative intervention it is necessary to inform the anesthesiologist about taking the drug by the patient.